{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:09:14Z","timestamp":1781719754349,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1208\/s12249-020-01906-7","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T18:02:43Z","timestamp":1610301763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Determination and Comparison of the Solubility, Oil\u2013Water Partition Coefficient, Intestinal Absorption, and Biliary Excretion of Carvedilol Enantiomers"],"prefix":"10.1208","volume":"22","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,10]]},"reference":[{"issue":"6","key":"1906_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/ejhf.81","volume":"16","author":"R B\u00f8lling","year":"2014","unstructured":"B\u00f8lling R, Scheller NM, K\u00f8ber L, Poulsen HE, Gislason GH, Torp-Pedersen C. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study. Eur J Heart Fail. 2014;16(6):678\u201384.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1906_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/FJC.0000000000000217","volume":"65","author":"YP Sun","year":"2015","unstructured":"Sun YP, Wei CP, Ma SC, Zhang YF, Qiao LY, Li DH, et al. Effect of carvedilol on serum heart-type fatty acid-binding protein, brain natriuretic peptide, and cardiac function in patients with chronic heart failure. J Cardiovasc Pharmacol. 2015;65(5):480\u20134.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"1906_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.7863\/ultra.34.3.483","volume":"34","author":"X Wang","year":"2015","unstructured":"Wang X, Wu J, Zhu D, You J, Zou Y, Qian J, et al. Characterization of coronary flow reserve and left ventricular remodeling in a mouse model of chronic aortic regurgitation with carvedilol intervention. J Ultrasound Med. 2015;34(3):483\u201393.","journal-title":"J Ultrasound Med"},{"issue":"4","key":"1906_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.cardiores.2004.05.014","volume":"63","author":"TA Koshimizu","year":"2004","unstructured":"Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004;63(4):662\u201372.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1906_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/157016112799959323","volume":"10","author":"M Wehland","year":"2012","unstructured":"Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmacol. 2012;10(3):378\u201390.","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"1906_CR6","doi-asserted-by":"publisher","first-page":"e000230","DOI":"10.1136\/openhrt-2014-000230","volume":"2","author":"JJ DiNicolantonio","year":"2015","unstructured":"DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, et al. Beta-blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015;2(1):e000230.","journal-title":"Open Heart"},{"issue":"9","key":"1906_CR7","first-page":"CD013438","volume":"9","author":"H Blessberger","year":"2019","unstructured":"Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager O, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery. Cochrane Database Syst Rev. 2019;9(9):CD013438.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1906_CR8","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.5114\/amsad.2016.63002","volume":"1","author":"WS Aronow","year":"2016","unstructured":"Aronow WS. Update of treatment of heart failure with reduction of left ventricular ejection fraction. Arch Med Sci Atheroscler Dis. 2016;1(1):e106\u201316.","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"1","key":"1906_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bcpt.12396","volume":"117","author":"FY Fisker","year":"2015","unstructured":"Fisker FY, Grimm D, Wehland M. Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure. Basic Clin Pharmacol Toxicol. 2015;117(1):5\u201314.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1906_CR10","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.biopha.2018.10.005","volume":"108","author":"D Meng","year":"2018","unstructured":"Meng D, Li Z, Wang G, Ling L, Wu Y, Zhang C. Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells. Biomed Pharmacother. 2018;108:1617\u201327.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1906_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4253\/wjge.v7.i5.532","volume":"7","author":"S Abid","year":"2015","unstructured":"Abid S, Ali S, Baig MA, Waheed AA. Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc. 2015;7(5):532\u20139.","journal-title":"World J Gastrointest Endosc"},{"issue":"5","key":"1906_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00003088-199426050-00002","volume":"26","author":"T Morgan","year":"1994","unstructured":"Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26(5):335\u201346.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 11","key":"1906_CR13","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1097\/00005344-198710111-00015","volume":"10","author":"G Neugebauer","year":"1987","unstructured":"Neugebauer G, Akpan W, M\u00f6llendorff v E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S85\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"1906_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3109\/10837450.2015.1073740","volume":"21","author":"JM Alves","year":"2016","unstructured":"Alves JM, Prado LD, Rocha HV. Evaluation and correlation of the physicochemical properties of carvedilol. Pharm Dev Technol. 2016;21(7):856\u201366.","journal-title":"Pharm Dev Technol"},{"issue":"4","key":"1906_CR15","first-page":"749","volume":"19","author":"M Fujimaki","year":"1991","unstructured":"Fujimaki M, Shintani S, Hakusui H. Stereoselective metabolism of carvedilol in the rat. Use of enantiomerically radiolabeled pseudoracemates. Drug Metab Dispos. 1991;19(4):749\u201353.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1906_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3109\/00498259009046823","volume":"20","author":"M Fujimaki","year":"1990","unstructured":"Fujimaki M, Hakusui H. Identification of two major biliary metabolites of carvedilol in rats. Xenobiotica. 1990;20(10):1025\u201334.","journal-title":"Xenobiotica."},{"issue":"9","key":"1906_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059\u201377.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1906_CR18","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/jps.23548","volume":"102","author":"X Yuan","year":"2013","unstructured":"Yuan X, Capomacchia AC. Influence of physicochemical properties on the in vitro skin permeation of the enantiomers, racemate, and eutectics of ibuprofen for enhanced transdermal drug delivery. J Pharm Sci. 2013;102(6):1957\u201369.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1906_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1871526517666170329123845","volume":"18","author":"H Alkadi","year":"2018","unstructured":"Alkadi H, Jbeily R. Role of chirality in drugs: an overview. Infect Disord Drug Targets. 2018;18(2):88\u201395.","journal-title":"Infect Disord Drug Targets"},{"issue":"4","key":"1906_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/chir.530010404","volume":"1","author":"AJ Nichols","year":"1989","unstructured":"Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr. The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1989;1(4):265\u201370.","journal-title":"Chirality."},{"issue":"Suppl 2","key":"1906_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/BF01409476","volume":"38","author":"G Neugebauer","year":"1990","unstructured":"Neugebauer G, Akpan W, Kaufmann B, Reiff K. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol. 1990;38(Suppl 2):108\u201311.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1906_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2131\/jts.43.59","volume":"43","author":"M Iwaki","year":"2018","unstructured":"Iwaki M, Niwa T, Nakamura Y, Kawase A, Komura H. Relative contribution of rat CYP isoforms responsible for stereoselective metabolism of carvedilol. J Toxicol Sci. 2018;43(1):59\u201363.","journal-title":"J Toxicol Sci"},{"issue":"3\u20134","key":"1906_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ejps.2009.04.009","volume":"37","author":"FL Mota","year":"2009","unstructured":"Mota FL, Carneiro AP, Queimada AJ, Pinho SP, Macedo EA. Temperature and solvent effects in the solubility of some pharmaceutical compounds: measurements and modeling. Eur J Pharm Sci. 2009;37(3\u20134):499\u2013507.","journal-title":"Eur J Pharm Sci"},{"key":"1906_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejps.2015.05.008","volume":"76","author":"A Andr\u00e9s","year":"2015","unstructured":"Andr\u00e9s A, Ros\u00e9s M, R\u00e0fols C, Bosch E, Espinosa S, Segarra V, et al. Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts. Eur J Pharm Sci. 2015;76:181\u201391.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"1906_CR25","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/jps.10081","volume":"91","author":"SC Sutton","year":"2002","unstructured":"Sutton SC, Rinaldi MT, McCarthy JM, Vukovinsky KE. A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression. J Pharm Sci. 2002;91(4):1046\u201353.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1906_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1208\/s12249-015-0365-2","volume":"17","author":"R Hamed","year":"2016","unstructured":"Hamed R, Awadallah A, Sunoqrot S, Tarawneh O, Nazzal S, AlBaraghthi T, et al. pH-dependent solubility and dissolution behavior of carvedilol--case example of a weakly basic BCS class II drug. AAPS PharmSciTech. 2016;17(2):418\u201326.","journal-title":"AAPS PharmSciTech"},{"key":"1906_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jpba.2016.09.019","volume":"138","author":"G Orgov\u00e1n","year":"2017","unstructured":"Orgov\u00e1n G, Gonda I, Nosz\u00e1l B. Biorelevant physicochemical profiling of (E)- and (Z)-resveratrol determined from isomeric mixtures. J Pharm Biomed Anal. 2017;138:322\u20139.","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"1906_CR28","first-page":"472","volume":"71","author":"T Incecayir","year":"2016","unstructured":"Incecayir T, Ilbasmis-Tamer S, Tirnaksiz F, Degim T. Assessment of the potential drug-drug interaction between carvedilol and clopidogrel mediated through intestinal P-glycoprotein. Pharmazie. 2016;71(8):472\u20137.","journal-title":"Pharmazie."},{"issue":"11","key":"1906_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11095-018-2486-2","volume":"35","author":"D Guo","year":"2018","unstructured":"Guo D, Yang H, Li Q, Bae HJ, Obianom O, Zeng S, et al. Selective inhibition on organic cation transporters by carvedilol protects mice from cisplatin-induced nephrotoxicity. Pharm Res. 2018;35(11):204.","journal-title":"Pharm Res"},{"issue":"4","key":"1906_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FJC.0b013e3182270783","volume":"58","author":"TF Solbach","year":"2011","unstructured":"Solbach TF, Grube M, Fromm MF, Zolk O. Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization. J Cardiovasc Pharmacol. 2011;58(4):409\u201317.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"1906_CR31","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1208\/s12249-018-1118-9","volume":"19","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Haeri A, Shahhosseini S, Dadashzadeh S. Labrasol-enriched nanoliposomal formulation: novel approach to improve oral absorption of water-insoluble drug, carvedilol. AAPS PharmSciTech. 2018;19(7):2961\u201370.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"1906_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/10837450.2013.795169","volume":"19","author":"MK Shah","year":"2014","unstructured":"Shah MK, Madan P, Lin S. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration. Pharm Dev Technol. 2014;19(4):475\u201385.","journal-title":"Pharm Dev Technol"},{"key":"1906_CR33","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.2147\/IJN.S91631","volume":"10","author":"AA Abdelbary","year":"2015","unstructured":"Abdelbary AA, Al-mahallawi AM, Abdelrahim ME, Ali AM. Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration. Int J Nanomedicine. 2015;10:6339\u201353.","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"1906_CR34","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3109\/10717544.2015.1013587","volume":"23","author":"HM Aboud","year":"2016","unstructured":"Aboud HM, Ali AA, El-Menshawe SF, Elbary AA. Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation. Drug Deliv. 2016;23(7):2471\u201381.","journal-title":"Drug Deliv"},{"key":"1906_CR35","doi-asserted-by":"publisher","first-page":"119510","DOI":"10.1016\/j.ijpharm.2020.119510","volume":"586","author":"RN Marreto","year":"2020","unstructured":"Marreto RN, Cardoso G, Dos Santos Souza B, Martin-Pastor M, Cunha-Filho M, Taveira SF, et al. Hot melt-extrusion improves the properties of cyclodextrin-based poly(pseudo)rotaxanes for transdermal formulation. Int J Pharm. 2020;586:119510.","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01906-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-020-01906-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01906-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T04:33:35Z","timestamp":1670733215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-020-01906-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-01906-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors confirm that this article content has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"43"}}